Gdh_17thedition_group 1.500

^ Akwa Tears® [OTC] see Artificial Tears on page 148
^ ALA see Aminolevulinic Acid on page 93
^ 5-ALA see Aminolevulinic Acid on page 93
^ Ala-Cort see Hydrocortisone (Topical) on page 886
^ Alamag [OTC] see Aluminum Hydroxide and Magnesium Hydroxide on page 81
^ Alamag Plus [OTC] see Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone
^ Ala-Scalp see Hydrocortisone (Topical) on page 886
^ Alavert® Allergy 24 Hour [OTC] see Loratadine on page 1087
^ Alavert® Children's Allergy [OTC] see Loratadine on page 1087
^ Alaway™ [OTC] see Ketotifen on page 1013
Albuterol (al BYOO ter ole)
Related Information
Medication Safety Issues
Sound-alike/look-alike issues:
Albuterol may be confused with Albutein®, atenololProventil® may be confused with Bentyl®, PriLOSEC®, Prinivil®Salbutamol may be confused with salmeterolVentolin® may be confused with phentolamine, Benylin®, Vantin Brand Names: U.S. AccuNeb®; ProAir® HFA; Proventil® HFA; Ventolin® HFA; VoSpire ER®
Brand Names: Canada Airomir; Apo-Salvent®; Apo-Salvent® AEM; Apo-Salvent® CFC
Free; Apo-Salvent® Sterules; Dom-Salbutamol; Med-Salbutamol; Mylan-Salbutamol Respi-rator Solution; Mylan-Salbutamol Sterinebs P.F.; Novo-Salbutamol HFA; Nu-Salbutamol; PHL-Salbutamol; PMS-Salbutamol; ratio-Ipra-Sal; ratio-Salbutamol; Sandoz-Salbutamol; Vento-lin®; Ventolin® Diskus; Ventolin® HFA; Ventolin® I.V. Infusion; Ventolin® Nebules P.F.
Index Terms Albuterol Sulfate; Salbutamol; Salbutamol Sulphate
Generic Availability (U.S.) Yes
Pharmacologic Category Beta2-Adrenergic Agonist
Use Treatment or prevention of bronchospasm in patients with reversible obstructive airway
disease; prevention of exercise-induced bronchospasm Contraindications Hypersensitivity to albuterol, adrenergic amines, or any component of the
Injection formulation (not available in U.S.): Patients with tachyarrhythmias Warnings/Precautions Optimize anti-inflammatory treatment before initiating maintenance
treatment with albuterol. Do not use as a component of chronic therapy without an anti-inflammatory agent. Only the mildest forms of asthma (Step 1 and/or exercise-induced) wouldnot require concurrent use based upon asthma guidelines. Patient must be instructed to seekmedical attention in cases where acute symptoms are not relieved or a previous level ofresponse is diminished. The need to increase frequency of use may indicate deterioration ofasthma, and treatment must not be delayed.
Use caution in patients with cardiovascular disease (arrhythmia or hypertension or HF),convulsive disorders, diabetes, glaucoma, hyperthyroidism, or hypokalemia. Beta-agonistsmay cause elevation in blood pressure, heart rate, and result in CNS stimulation/excitation.
Beta2-agonists may increase risk of arrhythmia, increase serum glucose, or decrease serumpotassium.
Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have beenreported. Do not exceed recommended dose; serious adverse events, including fatalities,have been associated with excessive use of inhaled sympathomimetics. Rarely, paradoxicalbronchospasm may occur with use of inhaled bronchodilating agents; this should bedistinguished from inadequate response. All patients should utilize a spacer device or valvedholding chamber when using a metered-dose inhaler.
Patient response may vary between inhalers that contain chlorofluorocarbons and thosewhich are chlorofluorocarbon-free.
Adverse Reactions (Reflective of adult population; not specific for elderly) Inci-
dence of adverse effects is dependent upon age of patient, dose, and route of administration.
Cardiovascular: Angina, atrial fibrillation, arrhythmias, chest discomfort, chest pain, extra- systoles, flushing, hyper-/hypotension, palpitation, supraventricular tachycardia, tachycardia Central nervous system: CNS stimulation, dizziness, drowsiness, headache, insomnia, irritability, lightheadedness, migraine, nervousness, nightmares, restlessness, seizure Dermatologic: Angioedema, rash, urticariaEndocrine & metabolic: Hyperglycemia, hypokalemia, lactic acidosis


Microsoft word - jutta

Dio: una parola ignorata? Jutta Burggraf Riproduciamo la conferenza della teologa Jutta Burggraf "Comunicare l'identità cristiana oggi", tenuta a Roma presso la Pontificia Università della Santa Croce il 27 aprile 2010 -7 mesi prima della sua morte- in occasione del congresso "Comunicazione della Chiesa, identità e dialogo". Dobbiamo parlare della trasmissione della f

Microsoft word - huff2.doc

Lake County Fair August 13, 14, 15, 16, 17, 18, 2013 MEMBER FAIR OF THE “BUCKEYE SUPER STAKES CIRCUIT” SPEED PROGRAM SATURDAY AUGUST 17, 2013 - POST TIME 1:00 P.M. DECLARE BEFORE WEDNESDAY, AUG. 14, 2013, 11:00 A.M. ‘12 Actual Purses Pace - 2 Year Old Filly “Buckeye Sweepstakes” - 1 Division . $4,410 Pace - 3 Year Old Filly “Buckeye Sweepstakes” - 1 D

Copyright © 2014 Articles Finder